Results 1 to 10 of about 3,317 (97)

The Effects of Xanthine Oxidoreductase Inhibitors on Oxidative Stress Markers following Global Brain Ischemia Reperfusion Injury in C57BL/6 Mice. [PDF]

PLoS ONE, 2015
We demonstrated that 3-nitrotyrosine and 4-hydroxy-2-nonenal levels in mouse brain were elevated from 1 h until 8 h after global brain ischemia for 14 min induced with the 3-vessel occlusion model; this result indicates that ischemia reperfusion injury ...
Masahiro Yamaguchi, Ken Okamoto, Teruo Kusano, Yoko Matsuda, Go Suzuki, Akira Fuse, Hiroyuki Yokota   +6 more
doaj   +2 more sources

Metabolomics analysis elucidates unique influences on purine / pyrimidine metabolism by xanthine oxidoreductase inhibitors in a rat model of renal ischemia-reperfusion injury [PDF]

Molecular Medicine, 2019
Background Clinically applied as anti-gout drugs, xanthine oxidoreductase (XOR) inhibitors, especially the potent, selective, non-purine-analog XOR inhibitors febuxostat and topiroxostat, exert organ-protective effects.
Takashi Tani, Ken Okamoto, Megumi Fujiwara, Akira Katayama, Shuichi Tsuruoka   +4 more
doaj   +2 more sources

The Effects of Topiroxostat, a Selective Xanthine Oxidoreductase Inhibitor, on Arterial Stiffness in Hyperuricemic Patients with Liver Dysfunction: A Sub-Analysis of the BEYOND-UA Study

Biomedicines, 2023
Background: The effects of uric acid (UA)-lowering therapy with xanthine oxidoreductase (XOR) inhibitors on the development of cardiovascular diseases remain controversial.
Yuya Fujishima, Hitoshi Nishizawa, Yusuke Kawachi, Takashi Nakamura, Seigo Akari, Yoshiyuki Ono, Shiro Fukuda, Shunbun Kita, Norikazu Maeda, Satoshi Hoshide, Iichiro Shimomura, Kazuomi Kario   +11 more
doaj   +3 more sources

Inhibition of xanthine oxidoreductase with febuxostat, but not allopurinol, prevents inflammasome assembly and IL-1β release [PDF]

Life Science Alliance
This study focuses on the underappreciated distinct effects of two clinically used xanthine oxidoreductase inhibitors: allopurinol and febuxostat. Besides reducing uric acid levels in gout treatment, febuxostat, but not allopurinol, prevents NLRP3 ...
Lauar de Brito Monteiro, Anne-Sophie Archambault, Lucas F Starchuk, Armando Alcazar, Ju Hee Oh, Joshua A Dubland, Bojana Rakić, Annette E Patterson, C Bruce Verchere, Ramon I Klein Geltink   +9 more
doaj   +2 more sources

Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies [PDF]

Frontiers in Endocrinology
Hyperuricemia is a metabolic disease caused by purine metabolism disorders. In recent years, its incidence has been increasing year by year and showing a trend of rejuvenation.
Xinze Li, Zilong Chen, Yanzhao Zhang, Chunyang Fan, Lulu Chen, Xiangman Xu, Jianying Chang, Wei Qiang, Hongwei Jiang, Chuanxin Liu   +9 more
doaj   +2 more sources

Allopurinol, Febuxostat, and Nonuse of Xanthine Oxidoreductase Inhibitor Treatment in Patients Receiving Hemodialysis: A Longitudinal Analysis

Kidney Medicine
Rationale & Objective: Allopurinol and febuxostat, which are xanthine oxidoreductase inhibitors, have been widely used as uric acid-lowering medications. However, evidence regarding their cardiovascular effects in hemodialysis is insufficient.
Takeo Ishii, Nodoka Seya, Masataka Taguri, Hiromichi Wakui, Ashio Yoshimura, Kouichi Tamura   +5 more
doaj   +3 more sources

Inhibitory effects of xanthine oxidase inhibitor, topiroxostat, on development of neuropathy in db/db mice

Neurobiology of Disease, 2021
Inflammation and oxidative stress contribute to the pathophysiology of diabetic neuropathy. According to recent evidence, the modulation of macrophage polarization in peripheral nerves represents a potential therapeutic target for diabetic neuropathy ...
Kazuhisa Takahashi, Hiroki Mizukami, Sho Osonoi, Saori Ogasawara, Yutaro Hara, Kazuhiro Kudoh, Yuki Takeuchi, Takanori Sasaki, Makoto Daimon, Soroku Yagihashi   +9 more
doaj   +1 more source

Association of Mutations Identified in Xanthinuria with the Function and Inhibition Mechanism of Xanthine Oxidoreductase

Biomedicines, 2021
Xanthine oxidoreductase (XOR) is an enzyme that catalyzes the two-step reaction from hypoxanthine to xanthine and from xanthine to uric acid in purine metabolism.
Mai Sekine, Ken Okamoto, Kimiyoshi Ichida   +2 more
doaj   +1 more source

Research advances in the therapeutic potential of xanthine oxidoreductase inhibitors for periodontitis

口腔疾病防治, 2023
Periodontitis is associated with abnormal purine metabolism, which is manifested by increased uric acid in host blood and increased expression of the purine-degrading enzyme, xanthine oxidoreductase (XOR), in periodontal tissues.
LI Yongshan , WU Zhicong, WANG Zixing, YU Xihuang, LIU Xi, YU Ting   +5 more
doaj   +1 more source

Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial.

PLoS ONE, 2022
BackgroundThe benefits of xanthine oxidase inhibitors to chronic heart failure (CHF) patients is controversial. We investigated the beneficial effects of a novel xanthine oxidoreductase inhibitor, topiroxostat, in patients with CHF and hyperuricemia (HU),
Masashi Sakuma, Shigeru Toyoda, Takuo Arikawa, Yota Koyabu, Toru Kato, Taichi Adachi, Hideaki Suwa, Jun-Ichi Narita, Koetsu Anraku, Kimihiko Ishimura, Fumitake Yamauchi, Yasunori Sato, Teruo Inoue   +12 more
doaj   +2 more sources